By creator to www.prnewswire.com
MANSFIELD, Mass., April 29, 2020 /PRNewswire/ — Eurofins -Transplant Genomics, Inc. (“TGI”), announce that Dr. Peter Meintjes will be part of the corporate as Chief Business Officer to guide the commercialization of TruGraf®, the one blood take a look at accepted by CMS for surveillance to rule out “silent” subclinical acute rejection in kidney transplant recipients with secure graft perform.
Dr. Meintjes joins TGI after six years at Omixon, world chief in pre-transplant HLA Typing, the place he departs as CEO, having grown the corporate at a CAGR of >75% since its first full 12 months of operation as a molecular diagnostics firm. Dr. Meintjes was interested in TGI by the distinctive alternative of commercializing TruGraf, a non-invasive blood take a look at, with established reimbursement that may verify the absence of “silent” subclinical acute rejection in kidney transplant recipients with secure renal perform. TruGraf is considerably differentiated compared with present donor derived cell-free DNA (ddcfDNA) and creatinine/eGFR post-transplant kidney monitoring exams, that are solely able to confirming energetic rejection in already injured kidneys, with out secure graft perform.
Dr. Meintjes joins Founder and CEO Dr. Stan Rose, who has led TGI by way of receiving a Native Protection Willpower (LCD) for TruGraf in November 2019. TruGraf additionally advantages from the potential CTOT-08 research, which demonstrated the prevalent incidence of silent subclinical rejection and the significance of early detection and therapy to long term outcomes. The scientific utility and validity of TruGraf had been established through the use of paired non-invasive liquid biopsies (blood samples) and invasive tissue biopsies (present gold normal for ruling out silent rejection) which demonstrated a 94% concordance. This highlights how TruGraf is the one take a look at that can be utilized for routine surveillance to deal with two essential unmet scientific wants for kidney transplant recipients:
- ~35% of sufferers with secure graft perform over two years are literally “silently” rejecting, and go untreated by ready for proof of scientific acute rejection (i.e. elevated creatinine or ddcfDNA), indicating injury already completed, and resulting in worse outcomes for sufferers
- ~75% of sufferers present process invasive surveillance biopsies weren’t experiencing any type of rejection, placing sufferers at pointless dangers from these invasive procedures
Through the use of TruGraf, nephrologists are empowered to make higher therapy choices for his or her sufferers. On the similar time, sufferers who take a look at detrimental are comforted by studying that they’ve satisfactory immune suppression (i.e. immune quiescence, graft stability, wholesome kidneys) with out having to be subjected to dangerous, expensive and painful biopsies.
With the sources of dad or mum firm Eurofins, TGI is positioning for robust development into the post-transplant kidney testing market after wonderful adoption amongst early clients. TGI is hiring further gross sales, medical science liaisons and advertising personnel to help the business enlargement.
Darren Lee, Vice President Transplant Advertising and marketing
Eurofins U.S. Scientific Diagnostics
508-337-6200 or [email protected]
About Eurofins – Transplant Genomics
Eurofins – Transplant Genomics (“TGI”) is a molecular diagnostics firm dedicated to enhancing organ transplant outcomes, with an preliminary concentrate on kidney transplant recipients. Working with the transplant group, TGI is commercializing a set of exams enabling analysis and prediction of transplant recipient immune standing. Check outcomes will help clinicians with data to optimize immune-suppressive remedy, improve affected person care and enhance graft survival. Check companies are supplied by way of TGI’s CLIA laboratory in Fremont, CA.
Eurofins – a worldwide chief in bio-analysis
Eurofins Scientific by way of its subsidiaries (hereinafter generally “Eurofins” or “the Group”) believes it’s a scientific chief in meals, setting, pharmaceutical and cosmetics merchandise testing and in agroscience CRO companies. Additionally it is one of many world unbiased market leaders in sure testing and laboratory companies for genomics, discovery pharmacology, forensics, CDMO, superior materials sciences and for supporting scientific research. As well as, Eurofins is among the main world rising gamers in specialty scientific diagnostic testing. With about 45,000 workers in additional than 800 laboratories throughout 47 international locations, Eurofins provides a portfolio of over 200,000 analytical strategies for evaluating the security, identification, composition, authenticity, origin and purity of organic substances and merchandise, in addition to for revolutionary scientific diagnostic. The Group goal is to offer its clients with high-quality companies, correct outcomes on time and skilled recommendation by its extremely certified workers.
Eurofins is dedicated to pursuing its dynamic development technique by increasing each its know-how portfolio and its geographic attain. By R&D and acquisitions, the Group attracts on the most recent developments within the discipline of biotechnology and analytical chemistry to supply its shoppers distinctive analytical options and essentially the most complete vary of testing strategies.
As one of the crucial revolutionary and high quality oriented worldwide gamers in its business, Eurofins is ideally positioned to help its shoppers’ more and more stringent high quality and security requirements and the increasing calls for of regulatory authorities world wide.
The shares of Eurofins Scientific are listed on the Euronext Paris Inventory Change (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press launch incorporates forward-looking statements and estimates that contain dangers and uncertainties. The forward-looking statements and estimates contained herein symbolize the judgment of Eurofins Scientific’s administration as of the date of this launch. These forward-looking statements should not ensures for future efficiency, and the forward-looking occasions mentioned on this launch might not happen. Eurofins Scientific disclaims any intent or obligation to replace any of those forward-looking statements and estimates. All statements and estimates are made based mostly on the data accessible to the Firm’s administration as of the date of publication, however no assure will be made as to their validity.
SOURCE Eurofins – Transplant Genomics
— to www.prnewswire.com